Biomarker Testing with DetermaRX for Lung Cancer Monitoring
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial studies certain indicators in blood and tissue to see if they can signal lung cancer or predict its return. It focuses on patients with lung nodules and those who have had lung cancer surgery. Researchers hope these indicators can help detect cancer early and identify high-risk patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you are actively receiving any cancer treatment, you would not be eligible to participate.
What makes the treatment DetermaRX unique for lung cancer monitoring?
DetermaRX is unique because it focuses on using biomarker testing to monitor lung cancer, which involves analyzing specific biological markers in the body to track the disease's progression and response to treatment. This approach is different from traditional treatments that may not utilize such targeted biomarker analysis for monitoring.12345
What data supports the effectiveness of the treatment DetermaRX for lung cancer monitoring?
The research highlights the importance of biomarker testing in lung cancer, which can help tailor treatments to individual patients. Although specific data on DetermaRX is not provided, the use of companion diagnostics in lung cancer has shown real-world benefits by identifying patients who are more likely to respond to targeted treatments.14678
Who Is on the Research Team?
Lary Robinson, MD
Principal Investigator
Moffitt Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults who may have early-stage lung cancer, with a lung nodule sized 8-40 mm and no spread to lymph nodes. They must be fit enough for surgery or radiotherapy at Moffitt Cancer Center, able to follow up, and consent to the study. Excluded are those with certain types of nodules, other active major cancers, prior lung cancer within 5 years, ongoing cancer treatment, inability to consent or incarceration.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Biomarker Evaluation
Evaluation of blood and tissue biomarkers to determine cancer risk and recurrence
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- DetermaRX
DetermaRX is already approved in United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
H. Lee Moffitt Cancer Center and Research Institute
Lead Sponsor